Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Sep-Oct;37(5):2203-2209.
doi: 10.21873/invivo.13320.

Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI)

Shinichiro Okauchi  1 , Gen Ohara  1 , Toshihiro Shiozawa  2 , Hiroko Watanabe  3 , Takeshi Numata  4 , Ryota Nakamura  4 , Tomohiro Tamura  5 , Norihiro Kikuchi  6 , Kunihiko Miyazaki  7 , Shigen Hayashi  8 , Hirofumi Sakurai  8 , Takaaki Yamashita  9 , Koichi Kurishima  10 , Masaharu Inagaki  11 , Takeo Endo  1 , Hiroichi Ishikawa  10 , Takayuki Kaburagi  5 , Hiroaki Satoh  12 , Toru Sakamoto  3 , Nobuyuki Hizawa  2
Affiliations
Observational Study

Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI)

Shinichiro Okauchi et al. In Vivo. 2023 Sep-Oct.

Abstract

Background/aim: Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) expressed on cancer cells derived from various organs and antigen-presenting cells and is currently commonly used in combination with chemotherapy. We conducted a study to clarify the current status of response to atezolizumab monotherapy in clinical practice and clarify the factors that contribute to long-term response and survival.

Patients and methods: We conducted a retrospective review of patients with advanced non-small cell lung cancer (NSCLC) treated with atezolizumab monotherapy from April 2018 to March 2023 at 11 Hospitals.

Results: The 147 patients evaluated had a progression-free survival (PFS) of 3.0 months and an overall survival of 7.0 months. Immune-related adverse events of any grade were observed in 13 patients (8.8%), grade 3 or higher in nine patients (6.1%), and grade 5 with pulmonary toxicity in one patient (0.7%). Favorable factors related to PFS were 'types of NSCLC other than adenocarcinoma'. Favorable factors for overall survival were 'performance status 0-1' and 'treatment lines up to 3'. There were 16 patients (10.9%) with PFS >1 year. No characteristic clinical findings were found in these 16 patients compared to the remaining 131 patients.

Conclusion: Efficacy and immune-related adverse events of NSCLC patients associated with atezolizumab monotherapy were comparable to those of previous clinical trial results. Knowledge of characteristics of patients who are most likely to benefit from atezolizumab monotherapy is a crucial step towards implementing appropriate prescribing.

Keywords: Atezolizumab; chemotherapy; immune-related adverse events; overall survival; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The Authors have no conflicts of interest to declare in relation to this study.

Figures

Figure 1
Figure 1. Treatment sequences for the 147 patients with non-small cell lung cancer who were treated with atezolizumab monotherapy.
Figure 2
Figure 2. In the 147 patients who were treated with atezolizumab monotherapy, median progression-free survival was 3.0 months [95% confidence interval (CI)=2.3-3.7 months] (A) and median overall survival was 7.0 months (95% CI=4.7-9.3 months) (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Khadela A, Postwala H, Rana D, Dave H, Ranch K, Boddu SHS. A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. Med Oncol. 2023;40(5):152. doi: 10.1007/s12032-023-02005-w. - DOI - PubMed
    1. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. doi: 10.1186/s12943-023-01740-y. - DOI - PMC - PubMed
    1. Gandara DR, Von Pawel J, Mazieres J, Sullivan R, Helland Å, Han J, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L. Atezolizumab treatment beyond progression in advanced NSCLC: Results from the randomized, phase III OAK study. J Thorac Oncol. 2018;13(12):1906–1918. doi: 10.1016/j.jtho.2018.08.2027. - DOI - PubMed
    1. Herbst RS, Giaccone G, De Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, Mccleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339. doi: 10.1056/NEJMoa1917346. - DOI - PubMed
    1. Ryu R, Ward KE. Atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC): Current status and future prospects. Front Oncol. 2018;8:277. doi: 10.3389/fonc.2018.00277. - DOI - PMC - PubMed

Publication types

MeSH terms